A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome
Sponsor: American College of Clinical Pharmacy
This PHASE1 trial investigates Membranous Nephropathy and Nephrotic Syndrome and is currently completed. American College of Clinical Pharmacy leads this study, which shows 11 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2022 — Oct 2023 [monthly]
Recruiting PHASE1
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1
-
Mar 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- American College of Clinical Pharmacy
- University of North Carolina, Chapel Hill
For direct contact, visit the study record on ClinicalTrials.gov .